Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triple Negative Breast Neoplasms × Toremifene × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Prostatic Neoplasms 3 Neoplasms, Hormone-Dependent 3 Carcinoma, Lobular 3 Carcinoma, Ductal, Breast 3 Prostatic Intraepithelial Neoplasia 2 Fractures, Bone 2 Desmoid Tumors 2 Triple Negative Breast Neoplasms 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Osteoporosis 1 Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Carcinoma In Situ 1 Breast Cancer Patients in Premenopausal 1 Bone Diseases, Metabolic 1

Interventions

pembrolizumab 141 Carboplatin 123 Paclitaxel 108 Cyclophosphamide 76 130-nm albumin-bound paclitaxel 59 Capecitabine 56 Gemcitabine 45 Doxorubicin 43 Albumin-Bound Paclitaxel 37 atezolizumab 36 Taxes 34 Cisplatin 32 Nivolumab 31 Docetaxel 28 Epirubicin 27 sacituzumab govitecan 26 olaparib 26 eribulin 24 Bevacizumab 24 durvalumab 23 Specimen Handling 23 camrelizumab 21 Magnetic Resonance Spectroscopy 20 Biopsy 20 Drug Therapy 18 toripalimab 16 Radiotherapy 14 liposomal doxorubicin 13 Everolimus 13 talazoparib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡